TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10368053
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene (OH)
Study: 8665547
Drug: Pramipexole (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (4.5 mg/day maximum)
Study: 2183619
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Methyldopa, Labetalol, No medication)
Study: 30111233
Drug: Electronic Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic Tablet (ET) classes
Study: 19915221
Drug: Cangrelor (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (intravenous, administered 30 minutes before PCI and continued for 2 hours after PCI)
Study: 19915221
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg oral loading dose, administered 30 minutes before PCI)
Study: 9701531
Drug: Rabeprazole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 30 mg
Study: 2553528
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (1500 aPTT once daily)
Study: 2553528
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin (5000 IU three times daily)
Study: 31104832
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of fIPV (Group D)
Study: 28899892
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy (ICBT) for 15 weeks
Study: 28899892
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy (CBGT) for 15 weeks
Study: 26658938
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Assistants (CTAs) with additional half-day training and a TT screening card
Study: 12535752
Drug: L-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine treatment in patients with subclinical hypothyroidism (SCH)
Study: 10908004
Drug: Eight models
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight models of outpatient treatment for methamphetamine dependence (treatment-as-usual)
Study: 1538597
Drug: No-touch technique
Normalized name: Lysol No-Touch Hand Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-touch technique without any other preparation aids (Group I)
Study: 1538597
Drug: Distention at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distention at 70-120 mm Hg with balanced pH electrolyte solution (Group II)
Study: 1538597
Drug: Distention at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distention at 70-120 mm Hg with balanced pH electrolyte solution plus nitroglycerin (1 microgram/ml) (Group III)
Study: 6377994
Drug: Intermittent Positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Positive Pressure Breathing (IPPB) for 15 min 4 times daily
Study: 6377994
Drug: Incentive Spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive Spirometry (IS) 4 times daily
Study: 6377994
Drug: Deep Breathing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Breathing Exercises (DBE) for 15 min 4 times daily
Study: 6377994
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no respiratory treatment)
Study: 24901305
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g carbohydrate (sucrose) 45 min before exercise
Study: 24901305
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 0.2 g · kg‐1 sodium bicarbonate (NaHCO3) 90 and 20 min before exercise
Study: 24901305
Drug: Placebo (H2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (H2O for carbohydrate group, 2 × 0.14 g · kg‐1 NaCl for sodium bicarbonate group)
Study: 20214718
Drug: LC 40
Normalized name: talc 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC 40 mg
Study: 20214718
Drug: LC 80
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LC 80 mg
Study: 18797094
Drug: Soft occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft occlusal splint therapy
Study: 18797094
Drug: Pharmacotherapy (muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (muscle relaxants and analgesics)
Study: 29092729
Drug: Zaltoprofen capsule
DrugBank: Zaltoprofen (DB06737)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Zaltoprofen capsule (80 mg) under fasting state
Study: 29092729
Drug: Zaltoprofen tablet
DrugBank: Zaltoprofen (DB06737)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Zaltoprofen tablet (80 mg) under fasting state
Study: 29092729
Drug: Zaltoprofen capsule
DrugBank: Zaltoprofen (DB06737)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Zaltoprofen capsule (80 mg) under fed state
Study: 29092729
Drug: Zaltoprofen tablet
DrugBank: Zaltoprofen (DB06737)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Zaltoprofen tablet (80 mg) under fed state
Study: 10702455
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg (Group T20)
Study: 10702455
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg (Group T40)
Study: 10702455
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 4 mL (Group NS)
Study: 8174947
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily) + Cisapride (20 mg twice daily)
Study: 3985039
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg daily)
Study: 3985039
Drug: Aerosol beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol beclomethasone (16 puffs daily)
Study: 15620828
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of piperacillin-tazobactam
Study: 6374680
Drug: Piretanide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (2 x 6 mg daily)
Study: 6374680
Drug: Hydrochlorothiazide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (2 x 25 mg daily)
Study: 6374680
Drug: Hydrochlorothiazide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (2 x 50 mg daily)
Study: 30022544
Drug: BF-200 ALA
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF-200 ALA gel (7.8% 5-aminolaevulinic acid)
Study: 30022544
Drug: MAL cream
Normalized name: PLO Transdermal Cream
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL cream (16% methyl-aminolaevulinate)
Study: 30022544
Drug: BF-200 ALA
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF-200 ALA gel
Study: 17428114
Drug: Rosiglitazone (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (2, 4, or 8 mg tablets once daily)
Study: 11860415
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg b.d.), Clarithromycin (500 mg b.d.), Amoxicillin (1 g b.d.)
Study: 11860415
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.d.), Bismuth subsalicylate (600 mg q.d.s.), Metronidazole (400 mg t.d.s.), Tetracycline (500 mg q.d.s.)
Study: 7615102
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) - 1,000 micrograms intranasal buserelin acetate daily for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Study: 7615102
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - no active treatment for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Study: 2798990
Drug: Phenformin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin (50 mg bid)
Study: 299896
Drug: Aspirin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (4 gm/day)
Study: 299896
Drug: Acetaminophen (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (14 days prior to each period)
Study: 30592553
Drug: Paxerol (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paxerol (325 mg acetaminophen and 150 mg ibuprofen per tablet) at low dose (1 tablet), mid dose (2 tablets), and high dose (3 tablets) for 14 days
Study: 30592553
Drug: Paxerol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paxerol (high dose)
Study: 25495209
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Orders (CTO)
Study: 23619906
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (250 mg magnesium oxide daily for 8 weeks)
Study: 16924991
Drug: Bleaching +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching + 10% sodium ascorbate solution
Study: 16924991
Drug: Bleaching (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching (10% carbamide peroxide gel)
Study: 15020394
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy by a research GP near their home address
Study: 16808802
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (25 mg/day)
Study: 10561343
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy (cisplatin 80 mg/m² on days 1 and 29, vindesine 3 mg/m² on days 1, 8, 29, and 36, mitomycin 8 mg/m² on days 1 and 29, RT starting on day 2 at 28 Gy)
Study: 10561343
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (same chemotherapy but RT initiated after completing CT at 56 Gy)
Study: 1789063
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms iodide/day (initial treatment) followed by 100 micrograms levothyroxine and 100 micrograms iodide/day (combination treatment)
Study: 7011035
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (2 million IU of penicillin G intramuscularly before and after the procedure, followed by 350 mg of pivampicillin three times daily for 4 days)
Study: 30177038
Drug: rhAPC (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhAPC (24 μg/kg/hr for ≤96 h antenatally)
Study: 2231833
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg flumazenil (group 1)
Study: 2231833
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flumazenil (group 2)
Study: 2231833
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg flumazenil (group 3)
Study: 2231833
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flumazenil (group 4)
Study: 2231833
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flumazenil
Study: 26786311
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (folic acid 2.5 mg/day, vitamin B6 50 mg/day, vitamin B12 1 mg/day)
Study: 24163081
Drug: Localized P2
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized P2 receptor blockade (pyridoxal‐5‐phosphate)
Study: 19596954
Drug: Lentinan plus
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan plus chemotherapy
Study: 15086284
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Study: 15086284
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Study: 15086284
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously once daily for 10 (+/‐4) days
Study: 12204931
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (graded exercise)
Study: 2698591
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of labor by stripping of membranes and i.v. oxytocin infusion, with artificial rupture of membranes when the cervical opening was 3 cm or more in diameter.
Study: 338079
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (10 g during the first 2 1/2 days)
Study: 27745812
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 (120 μg)
Study: 22801243
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G-GR) 1800 mg
Study: 16053850
Drug: Clonidine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (15 microg/ml)
Study: 16053850
Drug: Epinephrine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (12.5 microg/ml)
Study: 10065788
Drug: MH61 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MH61 monoclonal antibody
Study: 10065788
Drug: Two-color fluorescence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-color fluorescence staining with FITC-PSA and anti-CD46 monoclonal antibody
Study: 2207824
Drug: Propofol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.2 mg/kg)
Study: 29121415
Drug: Trametinib 2
Normalized name: trametinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 2 mg once daily until progressive disease, death, or unacceptable toxicity
Study: 23536942
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg/day for 4 weeks, then randomized to 125 mg/day (Group 1) or 250 mg/day (Group 2) for 12 weeks.
Study: 23536942
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg/day (Group 1)
Study: 23536942
Drug: Bosentan 250
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 250 mg/day (Group 2)
Study: 20967979
Drug: Local antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibacterial treatment consisting of bladder ionophoresis, vaginal exposure to estrogens, and vibromagnetic action of RECTOMASSAGER attachment and AMUS‐01‐INTRAMAG device
Study: 18687385
Drug: Valproate monotherapy
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate monotherapy for 6 weeks
Study: 12526235
Drug: Tracheal gas
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracheal gas insufflation (flow rate 6 L/min)
Study: 8102428
Drug: Dexamethasone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.4 mg/kg every 12 h for 2 days)
Study: 3463350
Drug: First 3
Normalized name: 3-Step First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: First 3 weeks of treatment (abstinent or not)
Study: 3463350
Drug: Remaining 3
Normalized name: Remain Gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaining 3 weeks of treatment (moderate drinker or not)
Study: 29379278
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (7 mL PRP solution)
Study: 29379278
Drug: Prolotherapy (PRL)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy (PRL) injection (7 mL 25% dextrose)
Study: 24623027
Drug: Diabetes Education
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes Education treatment
Study: 22555622
Drug: Venlafaxine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75 mg per day)
Study: 18567918
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice daily for 14 days
Study: 16266356
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER 40 mg
Study: 16266356
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER 20 mg
Study: 16266356
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER 20 mg and 40 mg
Study: 8871884
Drug: Famciclovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir (10 day course, oral)
Study: 1373429
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiotherapy (2 cycles)
Study: 1373429
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with radiosensitizing agent (3 cycles)
Study: 29903551
Drug: Conventional chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemoradiation treatment (60 Gy in 30 fractions)
Study: 24025633
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (9.7 to 10.7 mg/d)
Study: 24025633
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo, 1.3 to 1.4 mg/d)
Study: 20080256
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion of bupivacaine
Study: 19751371
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg twice daily
Study: 19751371
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg once daily
Study: 7524908
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (Ig) at a dose of 500 mg/kg every 2 weeks for the first 100 days post-BMT
Study: 7524908
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of anti-HCV antibodies
Study: 3365327
Drug: Deceptive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deceptive administration of placebo
Study: 3365327
Drug: Double-blind administration
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind administration of placebo
Study: 29618329
Drug: Digital exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital exercise prescription tool with standard lifestyle consultation for 3 months
Study: 20639738
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg + TENS
Study: 20639738
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg + TENS
Study: 20639738
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg + TENS placebo
Study: 20639738
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg + TENS placebo
Study: 20806385
Drug: Non-ablative 1,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative 1,550 nm fractional laser therapy (FLT) - 4-5 sessions at 15 mJ/microbeam, 14-20% coverage
Study: 20806385
Drug: Triple topical
Normalized name: Triple Paste Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple topical therapy (TTT) - hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream, applied once daily for 15 weeks
Study: 9832694
Drug: Calcium-channel antagonists
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel antagonists therapy
Study: 2730323
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for one day (n = 23)
Study: 2730323
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for four days (n = 27)
Study: 2730323
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for four days (n = 14)
Study: 29789414
Drug: Personalized fitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized fitting device using 3D scanning solution
Study: 27284581
Drug: Ultracaine DS
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultracaine DS Forte (treatment group)
Study: 19864082
Drug: Androgen suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression therapy (AST) plus radiation therapy (RT)
Study: 15653378
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 6 months
Study: 8554941
Drug: Ethanol 0.3
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.3 g kg-1 before an evening meal
Study: 8554941
Drug: Ethanol 0.3
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.3 g kg-1 after an evening meal
Study: 6105520
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (low dose)
Study: 6105520
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (high dose)
Study: 6105520
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (low dose)